$ADVM
Adverum Biotechnologies, Inc.

2017 Q4 Form 10-K Financial Statement

#000156459018004560 Filed on March 06, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 2016 Q4
Revenue $461.0K $1.849M $488.0K
YoY Change -5.53% 26.64% -49.17%
Cost Of Revenue $500.0K
YoY Change
Gross Profit $1.349M
YoY Change
Gross Profit Margin 72.96%
Selling, General & Admin $4.040M $20.86M $4.780M
YoY Change -15.48% -14.37% -10.99%
% of Gross Profit 1546.33%
Research & Development $12.01M $60.00K $7.900M
YoY Change 52.03% 650.0% -4.13%
% of Gross Profit 4.45%
Depreciation & Amortization $510.0K $2.100M $480.0K
YoY Change 6.25% 31.25% 60.0%
% of Gross Profit 155.67%
Operating Expenses $16.06M $60.00K $23.88M
YoY Change -32.75% 650.0% 57.71%
Operating Profit -$58.85M
YoY Change
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $810.0K $2.700M $220.0K
YoY Change 268.18% 254.33% 144.44%
Pretax Income -$14.79M -$56.15M -$23.17M
YoY Change -36.17% -50.97% 64.44%
Income Tax -$10.16M $0.00 -$780.0K
% Of Pretax Income
Net Earnings -$14.79M -$56.15M -$22.39M
YoY Change -33.96% -50.64% 58.89%
Net Earnings / Revenue -3208.03% -3036.61% -4588.93%
Basic Earnings Per Share
Diluted Earnings Per Share -$320.8K -$1.286M -$535.1K
COMMON SHARES
Basic Shares Outstanding 41.72M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $190.5M $190.5M $222.2M
YoY Change -14.27% -14.27% -14.24%
Cash & Equivalents $70.52M $70.50M $222.2M
Short-Term Investments $120.0M $120.0M
Other Short-Term Assets $3.300M $3.300M $2.200M
YoY Change 50.0% 50.0% 46.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $193.7M $193.7M $225.3M
YoY Change -14.0% -14.03% -13.69%
LONG-TERM ASSETS
Property, Plant & Equipment $3.024M $3.000M $4.169M
YoY Change -27.46% -28.57% 30.81%
Goodwill
YoY Change
Intangibles $5.000M $5.000M
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets $140.0K $100.0K $140.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $8.164M $8.200M $9.309M
YoY Change -12.3% -11.83% 179.8%
TOTAL ASSETS
Total Short-Term Assets $193.7M $193.7M $225.3M
Total Long-Term Assets $8.164M $8.200M $9.309M
Total Assets $201.9M $201.9M $234.6M
YoY Change -13.93% -13.94% -11.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.731M $1.700M $1.474M
YoY Change 17.44% 13.33% 143.64%
Accrued Expenses $7.000M $7.000M $6.500M
YoY Change 7.69% 7.69% 62.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.70M $10.70M $9.896M
YoY Change 8.12% 8.08% 50.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $481.0K $6.000M $386.0K
YoY Change 24.61% -23.08% -92.58%
Total Long-Term Liabilities $481.0K $6.000M $386.0K
YoY Change 24.61% -23.08% -92.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.70M $10.70M $9.896M
Total Long-Term Liabilities $481.0K $6.000M $386.0K
Total Liabilities $17.88M $17.90M $18.98M
YoY Change -5.83% -5.79% 61.87%
SHAREHOLDERS EQUITY
Retained Earnings -$254.1M -$197.9M
YoY Change 28.37% 135.14%
Common Stock $439.1M $413.5M
YoY Change 6.17% 22.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $184.0M $184.0M $215.6M
YoY Change
Total Liabilities & Shareholders Equity $201.9M $201.9M $234.6M
YoY Change -13.93% -13.94% -11.25%

Cashflow Statement

Concept 2017 Q4 2017 2016 Q4
OPERATING ACTIVITIES
Net Income -$14.79M -$56.15M -$22.39M
YoY Change -33.96% -50.64% 58.89%
Depreciation, Depletion And Amortization $510.0K $2.100M $480.0K
YoY Change 6.25% 31.25% 60.0%
Cash From Operating Activities -$12.20M -$45.42M -$8.350M
YoY Change 46.11% 18.38% -8.54%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K $1.016M -$920.0K
YoY Change -89.13% -57.88% 384.21%
Acquisitions
YoY Change
Other Investing Activities $34.79M -$121.2M $0.00
YoY Change -394.22% -100.0%
Cash From Investing Activities $34.70M -$122.2M -$920.0K
YoY Change -3871.74% -415.12% -103.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $16.52M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 16.65M 16.75M 210.0K
YoY Change 7828.57% 2890.71% -175.0%
NET CHANGE
Cash From Operating Activities -12.20M -45.42M -8.350M
Cash From Investing Activities 34.70M -122.2M -920.0K
Cash From Financing Activities 16.65M 16.75M 210.0K
Net Change In Cash 39.15M -151.7M -9.060M
YoY Change -532.12% -15734.12% -143.87%
FREE CASH FLOW
Cash From Operating Activities -$12.20M -$45.42M -$8.350M
Capital Expenditures -$100.0K $1.016M -$920.0K
Free Cash Flow -$12.10M -$46.44M -$7.430M
YoY Change 62.85% 13.87% -16.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5000000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
119966000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5000000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1850000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9896000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
352000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7099000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1250000
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1250000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
481000
CY2017Q4 us-gaap Liabilities
Liabilities
17877000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
439048000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-963000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-254062000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
184028000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
201905000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49015339
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49015339
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
96000
CY2016Q4 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6476000
CY2017Q4 us-gaap Assets
Assets
201905000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1731000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
531000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-111000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-312000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
487000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-190000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
762000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47453000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-47453000
CY2016 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
60714000
CY2015 us-gaap Restructuring Charges
RestructuringCharges
2573000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2700000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-56147000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-114522000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-775000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47453000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43661000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
149483000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
138954000
CY2015 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
218000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
188000
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
145000
CY2015 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
427000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
252592000
CY2016 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
64845000
CY2016 advm Adjustment To Additional Paid In Capital Remeasurement Of Contingent Common Stock Warrant
AdjustmentToAdditionalPaidInCapitalRemeasurementOfContingentCommonStockWarrant
8000
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
26000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11416000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
763000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
186000
CY2016 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
493000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-113747000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16519000
CY2017 advm Adjustment To Additional Paid In Capital Remeasurement Of Contingent Common Stock Warrant
AdjustmentToAdditionalPaidInCapitalRemeasurementOfContingentCommonStockWarrant
60000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8723000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
367000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
175000
CY2017 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
313000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-56147000
CY2015 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
11099000
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
230000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2096000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1603000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
812000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
8723000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
11416000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
11505000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-593000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-780000
CY2017 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
60000
CY2016 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8000
CY2015 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
218000
CY2017 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-10000
CY2015 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-21000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-886000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
437000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
491000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-71000
CY2015 advm Increase Decrease In Deposit And Other Noncurrent Assets
IncreaseDecreaseInDepositAndOtherNoncurrentAssets
3000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
333000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
724000
CY2017 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-25000
CY2016 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-988000
CY2015 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
1013000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1849000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3360000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2313000
CY2017 us-gaap Straight Line Rent
StraightLineRent
97000
CY2016 us-gaap Straight Line Rent
StraightLineRent
65000
CY2015 us-gaap Straight Line Rent
StraightLineRent
-207000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-45421000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-38366000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-35338000
CY2017 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
209787000
CY2015 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
88427000
CY2017 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1003000
CY2017 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
87596000
CY2016 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
37738000
CY2015 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
49850000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1016000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2412000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2992000
CY2016 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3449000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-122204000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
38775000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-41569000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16519000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
138954000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
367000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
763000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
188000
CY2017 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
313000
CY2016 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
493000
CY2015 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
427000
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
175000
CY2016 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
186000
CY2015 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
145000
CY2016 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
100000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
16748000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
556000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
138860000
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-774000
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-143000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-9000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-151651000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
822000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
61944000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221348000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159404000
CY2016 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
64845000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
115000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
180000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
178000
CY2017Q4 advm Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
57780000
CY2017Q4 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2017Q4 advm Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
57780000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates<font style="font-weight:normal;">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, intangible asset, fair values of financial instruments and fair value of common stock warrants. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#8217;s original estimates in any periods presented.</font></p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Other Uncertainties<font style="font-weight:normal;">&#8212;Financial instruments that potentially subject the Company to significant concentrations of credit risk consists primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#8217;s investment policy, which limits the Company&#8217;s investing to only those marketable securities rated at least A-1/P-1 Short Term Rating and A/A2 Long Term Rating, as determined by independent credit rating agencies. Management believes that the Company is not exposed to significant credit risk.</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#8217;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support the growth.</p></div>
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8300000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
230000
CY2017 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2015 us-gaap Payments For Restructuring
PaymentsForRestructuring
511000
CY2017 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-07-17
CY2017 dei Entity Information Date To Change Former Legal Or Registered Name
EntityInformationDateToChangeFormerLegalOrRegisteredName
2016-05-11
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.20
CY2015Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
15
CY2014Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2015 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
1049000
CY2015Q4 us-gaap Restructuring Reserve
RestructuringReserve
1013000
CY2016 us-gaap Payments For Restructuring
PaymentsForRestructuring
988000
CY2016Q4 us-gaap Restructuring Reserve
RestructuringReserve
25000
CY2017 us-gaap Payments For Restructuring
PaymentsForRestructuring
25000
CY2017Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
120148000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7100000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11200000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.99
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.35
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
183000
CY2017Q4 us-gaap Contractual Obligation
ContractualObligation
4200000
CY2017Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0
CY2017 us-gaap Maintenance Costs
MaintenanceCosts
500000
CY2016 us-gaap Maintenance Costs
MaintenanceCosts
600000
CY2017 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
CY2016 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
CY2017 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.91
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
119966000
CY2017Q4 advm Other Than Temporary Impaired Investments Available For Sale Securities
OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities
0
CY2017Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
169909000
CY2017Q4 advm Available For Sale Securities Debt Maturities After Year One Through Three Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesAfterYearOneThroughThreeAmortizedCostBasis
8019000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
177928000
CY2017Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
169758000
CY2017Q4 advm Available For Sale Securities Debt Maturities After Year One Through Three Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterYearOneThroughThreeFairValue
7988000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
177746000
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
177746000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
215916000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7697000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6763000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4673000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2594000
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2259000
CY2016Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2570000
CY2017Q4 advm Accrued Preclinical Costs
AccruedPreclinicalCosts
1255000
CY2016Q4 advm Accrued Preclinical Costs
AccruedPreclinicalCosts
1683000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2295000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
894000
CY2017Q4 advm Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
910000
CY2016Q4 advm Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
1142000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
245000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
187000
CY2017 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P4Y
CY2017 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-05-08
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1162000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1197000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
403000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2762000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1800000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1700000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1500000
CY2016 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
0
CY2017 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2016 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2015Q3 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
3
CY2015Q4 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
1
CY2017Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
13000000
CY2017 advm Share Based Compensation Arrangement By Share Based Payment Award Options Closing Price Of Common Stock Intrinsic Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsClosingPriceOfCommonStockIntrinsicValueAmount
3.5
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4800000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8900000
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8723000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11416000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11505000
CY2015 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2400000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-36923000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-96498000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-47235000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-19224000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-18024000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-218000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-19090000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-38938000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-16134000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
19000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
21000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
45000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-76000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1356000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1418000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
61000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
985000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
295000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Impairment Losses
IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
16834000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
507000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
326000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
910000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7935000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
16062000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
15277000
CY2017 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1495000
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
3231000
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
9000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
10163000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27142000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15785000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19889000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2586000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
3071000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2681000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3623000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3848000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4328000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1774000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
574000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1945000
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
274000
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
54000
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
64000
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
68000
CY2015Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
45000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35463000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23400000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
28888000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35463000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23400000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28839000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
49000
CY2015Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
49000
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1250000
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1250000
CY2015Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
49000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017 advm Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
0
CY2017 advm Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Balances Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxBalancesIncomeTaxExpenseBenefit
10200000
CY2017 advm Tax Cuts And Jobs Act Of2017 Incomplete Accounting One Time Transition Tax Rate Percent For Accumulated Foreign Earnings Related To Cash Assets
TaxCutsAndJobsActOf2017IncompleteAccountingOneTimeTransitionTaxRatePercentForAccumulatedForeignEarningsRelatedToCashAssets
0.155
CY2017 advm Tax Cuts And Jobs Act Of2017 Incomplete Accounting Transition Tax Rate Percent For Accumulated Foreign Earnings Related To Other Specified Assets
TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxRatePercentForAccumulatedForeignEarningsRelatedToOtherSpecifiedAssets
0.08
CY2017 advm Tax Cuts And Jobs Act Of2017 Incomplete Accounting Transition Tax Liability For Accumulated Foreign Earnings
TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxLiabilityForAccumulatedForeignEarnings
0
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12000000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-5300000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2745000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2157000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1568000
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
471000
CY2015 advm Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
172000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
588000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
589000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
925000
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2015 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9371000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8595000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6208000
CY2017Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
462000
CY2017Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
463000
CY2017Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
463000
CY2017Q4 us-gaap License And Services Revenue
LicenseAndServicesRevenue
461000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
17050000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
12556000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
15034000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
16056000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-16099000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-11430000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-13829000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-14789000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2016Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
265000
CY2016Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
307000
CY2016Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
395000
CY2016Q4 us-gaap License And Services Revenue
LicenseAndServicesRevenue
488000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
15773000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
62189000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
14902000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
23875000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-15392000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-61660000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-14301000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-22394000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.76
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2016Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
49100000
CY2016Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
400000
CY2016Q4 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
11200000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2200000

Files In Submission

Name View Source Status
0001564590-18-004560-index-headers.html Edgar Link pending
0001564590-18-004560-index.html Edgar Link pending
0001564590-18-004560.txt Edgar Link pending
0001564590-18-004560-xbrl.zip Edgar Link pending
advm-10k_20171231.htm Edgar Link pending
advm-20171231.xml Edgar Link completed
advm-20171231.xsd Edgar Link pending
advm-20171231_cal.xml Edgar Link unprocessable
advm-20171231_def.xml Edgar Link unprocessable
advm-20171231_lab.xml Edgar Link unprocessable
advm-20171231_pre.xml Edgar Link unprocessable
advm-ex1010_819.htm Edgar Link pending
advm-ex1013_1085.htm Edgar Link pending
advm-ex1014_1087.htm Edgar Link pending
advm-ex1016_1089.htm Edgar Link pending
advm-ex1017_1084.htm Edgar Link pending
advm-ex1030_1090.htm Edgar Link pending
advm-ex1036_1088.htm Edgar Link pending
advm-ex1043_1145.htm Edgar Link pending
advm-ex211_13.htm Edgar Link pending
advm-ex231_10.htm Edgar Link pending
advm-ex311_6.htm Edgar Link pending
advm-ex312_8.htm Edgar Link pending
advm-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2018030621522562539486.jpg Edgar Link pending
g2018030621522562939487.jpg Edgar Link pending
g2018030621524152040824.jpg Edgar Link pending
g2018030621524153140825.jpg Edgar Link pending
g2018030621524363640826.jpg Edgar Link pending
g2018030621525647340827.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending